Protagonist Therapeutics, Inc. is a biotech company developing new medicines.
Protagonist Therapeutics, Inc. (PTGX) is expected to report earnings on Thursday, November 5, 2026, after the close. Estimated release time 16:10 ET. Consensus EPS estimate is $2.39.
| Report date | Quarter | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|---|
| 2026-08-05 | Jun 2026 qtr | $2.27 | $2.47 | +8.8% | $213.47M |
| 2026-05-05 | Mar 2026 qtr | $-0.65 | $0.06 | — | — |
| 2026-02-25 | Dec 2025 qtr | $-0.53 | $-0.69 | — | $7.44M |
| 2025-08-06 | Jun 2025 qtr | $-0.53 | $-0.55 | -3.8% | $5.55M |
| 2025-05-06 | Mar 2025 qtr | $-0.50 | $-0.19 | — | — |
| 2025-02-21 | Dec 2024 qtr | $0.06 | $2.11 | — | $170.64M |
| 2024-08-06 | Jun 2024 qtr | $-0.50 | $-0.50 | +0.0% | $4.17M |
| 2024-05-07 | Mar 2024 qtr | $1.19 | $3.41 | — | $254.95M |
PTGX has beaten consensus EPS in 2 of its last 3 scored quarters.
See PTGX on the live calendar →